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Abstract
Background: Induction of the COX-2 isoenzyme appears to play a major role in the genesis of
central sensitization after nociceptive stimulation. This study aimed to investigate the efficacy of a
single, oral dose of the specific COX-2 inhibitor-valdecoxib in attenuating the central sensitization
– induced secondary hyperalgesia in a heat/capsaicin pain model in healthy volunteers.
Methods: The study was a randomized, double blind, placebo controlled, crossover, single dose
efficacy trial using 20 healthy volunteers. Two hours following placebo or 40 mg, PO valdecoxib,
participants underwent skin sensitization with heat/capsaicin, as well as supra-threshold pain and
re-kindling measurements according to an established, validated pain model. Subjects rated pain
intensity and unpleasantness on a visual analog scale and the area of secondary hyperalgesia was
serially mapped.
Results: The area of secondary hyperalgesia produced after 40 mg of valdecoxib was no different
than that after placebo. Furthermore, there were no significantly relevant differences when
volunteers were treated with valdecoxib or placebo in relation to either cold- or hot pain threshold
or the intensity of pain after supra-threshold, thermal pain stimulation.
Conclusion: We demonstrated that a single, oral dose of valdecoxib when does not attenuate
secondary hyperalgesia induced by heat/capsaicin in a cutaneous sensitization pain model in healthy
volunteers.
Background
Induction of the COX-2 isoenzyme appears to play a
major role in the genesis of central sensitization after noci-
ceptive stimulation, with combined central and periph-
eral COX-2 inhibition acting synergistically to reduce the
excitatory consequences of nociceptive input [1,2]. The
selective COX-2 inhibitors may offer significant advan-
tages over existing non-selective COX inhibitors by ena-
bling inhibition of the central sensitization component of
secondary hyperalgesia, in addition to their peripheral
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analgesic activity [3-8]. Several COX-2 inhibitors includ-
ing valdecoxib reach the central nervous system in
humans, with rapid penetration, and in concentrations
apparently sufficient to inhibit COX-2 activity [9].
To study the efficacy of valdecoxib in attenuating second-
ary hyperalgesia, we used the cutaneous heat-capsaicin
sensitization model. This model is well validated and
accepted for assessing secondary hyperalgesia and the effi-
cacy of analgesic medications and has been extensively
described [10-14]. The synergistic combination of non-
invasive physical (heat) and chemical (capsaicin) mecha-
nisms of nociceptor stimulation produces a relatively sta-
ble and long-lasting hyperalgesia with a low potential for
skin injury [15]. Both the heat and capsaicin act by activat-
ing nociceptors in the skin [15]. Rekindling is the key step
in the model that ensures continuous secondary hyperal-
gesia by providing a constant afferent signal from the site
of primary injury [10].
The specific aim of this study was to investigate the effect
of pretreatment with the COX-2 specific inhibitor val-
decoxib on the development of the secondary hyperalge-
sia in humans. The hypothesis to be tested is that selective
COX-2 inhibitors significantly attenuate the central com-
ponent of sensitization, thereby decreasing the area of sec-
ondary hyperalgesia induced by our heat/capsaicin pain
model.
Methods
This prospective, randomized, double-blinded study was
performed on 20 healthy adult volunteers (10 men and
10 women) using a crossover design (a single, oral dose of
placebo vs. valdecoxib 40 mg) separated by a minimum
one-week washout period. Subject treatment was deter-
mined according to a randomization scheme restricted by
gender and prepared by our department of Health Evalu-
ation Sciences and conveyed to our Investigational Drug
Service without communication to any of the investiga-
tors. On the day of testing either placebo or active drug
was dispensed by the pharmacist in envelopes marked
with the subject name and treatment number (1 or 2) to
one of the investigators. No treatment assignments were
reveled to the investigators until after the last subject com-
pleted the protocol and all data had been collected. To
further insure blinding subjects and investigators were
asked to guess which treatment they received on a partic-
ular day. Analysis of these guesses was not statistically
highly correlated with the actual treatment assignments.
All clinical components of the study were performed in
the clinical suites of the General Clinical Research Center
(GCRC) at the Penn State Milton S. Hershey Medical
Center. The Institutional Review Board approved the
experimental protocol and Informed Consent form prior
to initiation of the study.
All experimental sessions began at 7:00 am, following ver-
ification of Informed Consent, a negative pregnancy test,
and baseline vital signs. Hot and cold pain thresholds
were measured as well as the response to supra-threshold
pain stimuli were obtained at baseline. After baseline
measurements were obtained the subjects were given
either active drug or placebo orally. Measurements of hot/
cold pain thresholds were obtained 110 minutes after
study substance or placebo administration, followed by
initial heat-sensitization and application of capsaicin. The
area of secondary hyperalgesia (HA), as well as the hot
and cold pain threshold was measured at 160, 200, 240,
300, 340 and 400 minutes after placebo or study drug
administration. The response to the supra-threshold pain
stimulation was measured at 110 and 400 minutes after
placebo or study drug administration. To evaluate patient
blinding to study treatment, subjects were asked after each
experimental session; to indicate which treatment they
believed they had received (valdecoxib or placebo).
Hot/cold pain threshold measurements
The pain threshold induced by hot and cold stimuli was
determined by increasing the stimulus level until the sen-
sation was perceived as painful, at which time the subject
stopped the stimulus. Thermal stimulation was conducted
using a 9 cm2 thermode on the subject's non-dominant
forearm. The thermode is controlled by a computerized
regulator that starts at 32°C then warms or cools the sur-
face of the thermode at a linear rate of 1°C/sec with a
safety cutoff of 50°C or 0°C, for heat and cold, respec-
tively (TSAII NeuroSensory Analyzer from Medoc
Advanced Medical Systems, U.S., Minneapolis, MN). The
subjects were instructed to terminate the heating or cool-
ing at the initial perception of pain at which point the
thermode temperature would return to baseline. Two
series of cold and then hot thresholds were measured with
four stimuli in each series and the average of the eight tri-
als recorded.
Supra-threshold pain measurements
Supra-threshold pain measurements were also performed
on the medial aspect of the non-dominant forearm.
Supra-threshold pain measurements were initiated at
32°C and progressed linearly at 1°C /sec. to a maximum
of 48°C and then held there for 5 seconds. This session
could as well be terminated at any time if the subject per-
ceived the stimulus unacceptably painful or unpleasant.
Study subjects were asked to report the level of perceived
pain intensity (algosity) and unpleasantness by means of
a 100 mm visual analog scale (VAS) for each pain aspect
immediately after each stimulus. Before starting all meas-
urements, an explanation was provided regarding the dif-
ferences between the two aspects of pain: namely algosity
(the sensory dimension of pain intensity) and unpleasant-
ness (the emotional dimension of pain). To illustrate theBMC Anesthesiology 2006, 6:3 http://www.biomedcentral.com/1471-2253/6/3
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differences between the domains, a loud noise analogy
was used: the volume of the music represents the painful-
ness, and the obtrusiveness of the music represents the
unpleasantness. The VAS ranged from "no pain" at one
end to "the worst pain imaginable" at the other end. For
measurement of unpleasantness, the wording was
changed in accordance with "no unpleasantness" on one
end and "the most unpleasant feeling" on the other end.
The results were the average of two stimulation sessions.
Cutaneous sensitization and rekindling
Cutaneous sensitization was performed by heating the
skin on the volar aspect of the dominant forearm to 45°C
for 5 minutes. Immediately thereafter, 0.5 g of capsaicin
cream 0.075% (Capsagesic-HP) was applied to the heated
area of skin and covered with a transparent dressing. After
30 minutes the dressing and capsaicin was removed. To
ensure continuous secondary hyperalgesia, skin sensitiza-
tion was rekindled (RK) 70 minutes after the initial appli-
cation of the thermode, and at 40-minute intervals
thereafter. Rekindling was achieved by reheating the pre-
viously sensitized skin to 40°C for 5 minutes.
Secondary hyperalgesia (HA) measurements
Assessment of hyperalgesia was performed on the volar
aspect of the dominant forearm after initial thermode/
capsaicin skin sensitization as well as after subsequent
rekindling. After heat stimulation the area of secondary
hyperalgesia was quantified with a foam brush (allody-
nia) and a 26 g von Frey hair (mechanical hyperalgesia)
by stimulating the skin distant from the treated area and
slowly moving inward until the subject indicated the stim-
ulus had become noxious or until the subject reported a
definite change in sensation (i.e., burning, tenderness,
more intense pricking). The borders were marked with a
felt pen, and the rostral-caudal and lateral-medial dis-
tances were measured for later calculation of surface area
using a rectangular model (length of longer side × length
of shorter side).
Statistical analysis
Data are presented as mean +/- SD (see figures). The pri-
mary outcome measure was the surface area of secondary
hyperalgesia to both brush and von Frey hair simulation
(measured at 40 minutes intervals for 6 hours after heat-
capsaicin sensitization). The secondary measures
included hot/cold pain thresholds and painfulness of the
supra-threshold stimulation. The statistical comparison of
the results (between placebo and valdecoxib pretreated)
was performed using the two-tailed Wilcoxon signed
ranks test. The calculation of sample size was based on a
power calculation using our own preliminary data indi-
cating that a minimum number of 20 volunteers is
required to achieve 80% power (type II error at 0.2) to
detect a clinically relevant change of 30% or more in the
area of secondary hyperalgesia with alpha = 0.05 (paired,
two-tailed test). A p-value equal to or less than 0.05 was
considered statistically significant.
Results
Measurement of the success of blinding
At the end of each study session, 45% of the valdecoxib
recipients and 20% of the placebo recipients correctly
identified their group assignment (p = 0.092, Chi-square
test).
Pain threshold measurements
The results of the cold- and warm-threshold are presented
in Figure 1A and 1B. No differences in the baseline cold-
The effect of valdecoxib (40 mg, PO) and placebo on cold-  (panel A) and hot (panel B) pain threshold Figure 1
The effect of valdecoxib (40 mg, PO) and placebo on cold- 
(panel A) and hot (panel B) pain threshold. The pain thresh-
old is expressed in °C (mean ± SD). Time scale indicates the 
time (in min) after study drug or placebo administration and 
when the pain measurements were performed. Black col-
umns represent valdecoxib administration; white columns 
represent placebo administration. The results were com-
pared using the Wilcoxon signed ranks test.BMC Anesthesiology 2006, 6:3 http://www.biomedcentral.com/1471-2253/6/3
Page 4 of 7
(page number not for citation purposes)
pain threshold were noted in the study volunteers. The
mean cold-pain threshold did not significantly differ
between the placebo- and valdecoxib-pretreated groups at
any time (160–400 minutes) following administration of
study drug (Figure 1A). Similarly, no differences in the
baseline hot-pain threshold were observed either before
administration of valdecoxib/placebo or at any time
thereafter (Figure 2B).
Painfulness of the supra-threshold stimulation
Baseline visual analog scores for pain algosity (Fig. 2A)
and pain unpleasantness (Fig. 2B) were not statistically
different at baseline or at either investigated time (1 and 6
hours) after valdecoxib or placebo administration.
Heat-capsaicin sensitization method
The heat-capsaicin sensitization method produced a large
area of secondary hyperalgesia around the area of primary
hyperalgesia (skin area directly stimulated by the ther-
mode). The area of secondary hyperalgesia was character-
ized by allodynia (pain response to a previously non-
noxious stimulus) and hyperalgesia (increased pain
response to a noxious stimulus). Although rekindling
maintained an area of secondary hyperalgesia, its size
gradually diminished to approximately 50% of its initial
size after five re-kindling sessions. This decline in size was
more pronounced for brush hyperalgesia (allodynia) than
for mechanical hyperalgesia using the von Frey hair. The
area of allodynia (sensitivity to brush stimulation) was
not statistically different between placebo and valdecoxib
administration sessions (p > 0.05, Wilcoxon signed ranks
test) at any time (160–400 minutes) (see Fig. 3A). Simi-
larly, the area of hyperalgesia (sensitivity to von Frey hair
stimulation) was not significantly different between pla-
cebo or valdecoxib administration sessions (p > 0.05, Wil-
coxon signed ranks test) (Fig. 3B). The post hoc
calculation of the power of the study, based on expected
level of significance (P = 0.05), and the sensitivity thresh-
old to detect a 30% reduction in the areas of mechanical
hyperalgesia, revealed power values of 0.851, 0.929,
0.9756, 0.9665, 0.9564 and 0.9643 for all measurements
taken between 160 and 400 min (i.e., at HA1 through
HA6, respectively) after study drug or placebo administra-
tion. In contrast, when the post hoc power calculations
were performed for the brush allodynia measurements,
the sufficient power values (i.e., power value more than
0.8) were demonstrated only for the measurements taken
at HA1 (160 min), HA2 (200 min) and HA3 (240 min)
study drug or placebo administration (power values of
0.815, 0.805, 0.801, respectively).
Adverse events
All 20 volunteers completed the study. The subjects toler-
ated the study medication and experimental procedures,
and no adverse events were noted.
Discussion
The main goal of the study was to answer the question
whether an administration of the COX-2 inhibitor will
reduce responses to heat/capsaicin induced hypersensitiv-
ity in humans. We showed that the administration of 40
mg of valdecoxib had no effect on skin sensitization in the
heat-capsaicin model. Furthermore, valdecoxib had no
analgesic effect following thermal/chemical sensitization
The effect of valdecoxib (40 mg, PO) and placebo on algosity  (panel A) and unpleasantness (panel B) of the supra-maximal  pain stimulus Figure 2
The effect of valdecoxib (40 mg, PO) and placebo on algosity 
(panel A) and unpleasantness (panel B) of the supra-maximal 
pain stimulus. The pain intensity is expressed in the visual 
analog scale of pain units (0 = no pain, 100 = maximum pain) 
as mean ± SD. Time scale indicates the time (in min) after 
study drug or placebo administration and when the pain 
measurements were performed. Black columns represent 
valdecoxib administration; white columns represent placebo 
administration. The results were compared using the Wil-
coxon signed ranks test.BMC Anesthesiology 2006, 6:3 http://www.biomedcentral.com/1471-2253/6/3
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(i.e., thermal pain threshold, intensity of the supra-thresh-
old heat stimulation), when compared to baseline or pla-
cebo. The observed results were obtained during the
period of time corresponding to the recently reported
maximal plasma and cerebral spinal fluid, concentration
after single 40 mg oral dose of valdecoxib [9]. It was also
demonstrated that the single oral dose of 40 mg produced
maximum plasma concentrations at 2 hrs after adminis-
tration and lasting virtually undiminished (75% of maxi-
mum plasma concentration) until 6 hours post-
administration [9]. In addition, the same authors demon-
strated that valdecoxib produced maximum concentra-
tions within the cerebrospinal fluid at 2 hours after
administration, which lasted unchanged for another 6
hours. These results indicate that the pain measurements
employed in our study were performed during the time of
maximum concentrations of valdecoxib in both plasma
and the central nervous system.
The current study is negative, which indicates either that
the drug is ineffective or that the test is insensitive. The
only way to demonstrate internal sensitivity of the test
would have been to introduce a positive control. Not hav-
ing the positive control included, we performed post-hoc
calculations in order to demonstrate the power of the
study regarding secondary hyperalgesia. The calculated
power of the study exceeded 0.8 with data collected from
20 study volunteers (in paired design) for both measured
components of the hyperalgesia response for at least ini-
tial half of all measurements (i.e., at HA1 through HA3),
based on expected level of significance (P = 0.05), and the
sensitivity threshold to detect a 30% reduction in the areas
of hyperalgesia. In other words, the probability of type II
error (i.e., not being able to demonstrate the presumable
difference between placebo and valdecoxib) was less than
20%. It has been shown that an identical QST and heat-
capsaicin model (including in many cases identical appa-
ratus, thermode and the study protocol) had sufficient
sensitivity in human volunteers to demonstrate the anal-
gesic effects of intravenous infusion of low-doses of alfen-
tanil [12], ramifentanil [14,16], lidocaine [17],
intrathecally [12], but not systemically [18], administered
adenosine, as well as orally administered gabapentin [11].
On the other hand, Mikkelsen et al. failed to demonstrate
the analgesic efficacy of intravenous magnesium using a
similar technique [13], and they reported that the effect of
lidocaine was very modest [17]. Other investigations have
demonstrated a correlation between the pre- and post-
operative pain thresholds [18,19], using QST as well as for
the prediction of the analgesic outcome after 3 steroid
injections in sciatica [20]. Taken together, we can assume
that the combined QST/heat-capsaicin method is suffi-
ciently specific and sensitive for evaluation of analgesia in
healthy volunteers. It is, however, possible that the level
of sensitivity obtained by using this technique (i.e. 30%
reduction in the surface area) is insufficient to detect the
minimal analgesic effects of oral valdecoxib on secondary
hyperalgesia.
Previous animal studies suggest that COX2 inhibitors may
have different effect on the development of the secondary
hypersensitivity, depending on the drug [21,22] and
experimental model [23]. There is evidence that topical
COX2 inhibition is effective in capsaicin pain model in
humans [24]. The results of our study seem to partially
contradict the above-presented data. On the other several
The effect of valdecoxib (40 mg, PO) and placebo on the skin  area of allodynia (panel A) and mechanical hyperalgesia (panel  B) after skin heat/capsaicin sensitization performed 120 min  after study drug or placebo administration Figure 3
The effect of valdecoxib (40 mg, PO) and placebo on the skin 
area of allodynia (panel A) and mechanical hyperalgesia (panel 
B) after skin heat/capsaicin sensitization performed 120 min 
after study drug or placebo administration. The areas of allo-
dynia (response to paint brush stimulation) and mechanical 
hyperalgesia (response to von Frey hair stimulation) are 
expressed as mean ± SD in cm2. Time scale indicates the 
time (in min) after study drug or placebo administration and 
when the pain measurements were performed. Black col-
umns represent valdecoxib administration; white columns 
represent placebo administration. The results were com-
pared using the Wilcoxon signed ranks test.BMC Anesthesiology 2006, 6:3 http://www.biomedcentral.com/1471-2253/6/3
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animal studies demonstrated lack of efficacy of COX
inhibitors against acute noxious heat stimuli in the nor-
mal condition (i.e., without previous sensitization [25-
27]. These studies would lead one to predict that this
COX-2 inhibitor would have no effect on acute thermal
heat responses, either threshold or supra-threshold (as
was observed), but that it might have efficacy against
hypersensitivity. The negative results in this study should
be therefore attributed rather to experimental design,
including experimental model, but also the use of pre-
treatment, which does not allow observing changes from
the untreated baseline during placebo session. On the
other hand it is important to note that a similar lack of
effect of valdecoxib to prevent visceral pain hypersensitiv-
ity in healthy volunteers was demonstrated recently in a
validated human esophageal pain hypersensitivity model
[28]. Finally, it was demonstrated previously, that the
main cause of the variability in pain trials might be ran-
dom chance associated with the relatively small size of the
trial group [29]. It is therefore possible, that the results of
this study, which contradicts clinical experience and trial
results in clinical pain states, might be due to the random
play of chance, and us such need to be confirmed in larger
studies or from pooling multiple trials of conventional
(small) size).
Conclusion
We demonstrated in a double-blind, cross-over, prospec-
tive study that a single, orally administered dose of val-
decoxib does not attenuate secondary hyperalgesia/
allodynia induced by the skin heat/capsaicin sensitization
model, when compared to placebo.
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